2012-04-30 – Page 2 – China Stock Advice

CYD [CHINA YUCHAI INTERNATIONAL] 6-K: CHINA YUCHAI INTERNATIONAL TO ANNOUNCE – Audio Web

[CHINA YUCHAI INTERNATIONAL TO ANNOUNCE - Audio Web Cast to Begin at 8:00 AM EDT - Singapore, Singapore April 30, 2012 http://www.cyilimited.com The webcast can be accessed at the investor relations section of the Companys website located at About China Yuchai International http://www.cyilimited.com China Yuchai International Limited, through its subsidiary, Guangxi Yuchai Machinery Company Limited (GYMCL), engages in the]

By info| 2016-03-02T22:58:02+00:00 April 30th, 2012|Categories: Chinese Stocks, CYD, Webplus ver|Tags: 0000932695, 2012-04-30, 3510, 6-K, CYD, ENGINES and TURBINES|0 Comments

CPHI [CHINA PHARMAS,] 8-K: (Original Filing)

[AMENDMENT AGREEMENT TO NON-QUALIFIED STOCK OPTION AGREEMENTS OF CHINA PHARMA HOLDINGS, INC WHEREAS, the Employment Agreement by and between the Company and the Optionee will cease its effect as of April 28, 2012; WHEREAS, the Nominating and Compensation Committee believes it is for the best interest of the Company to terminate the Subject Options on April 28, 2012 and the]

By info| 2016-03-03T17:47:41+00:00 April 30th, 2012|Categories: Chinese Stocks, CPHI, SEC Original|Tags: 0001106644, 2012-04-30, 2834, 8-K, CPHI, PHARMACEUTICAL PREPARATIONS|0 Comments

CPHI [CHINA PHARMAS,] 8-K: AMENDMENT AGREEMENT TO NON-QUALIFIED STOCK OPTION AGREEMENTS OF

[AMENDMENT AGREEMENT TO NON-QUALIFIED STOCK OPTION AGREEMENTS OF CHINA PHARMA HOLDINGS, INC WHEREAS, the Employment Agreement by and between the Company and the Optionee will cease its effect as of April 28, 2012; WHEREAS, the Nominating and Compensation Committee believes it is for the best interest of the Company to terminate the Subject Options on April 28, 2012 and the]

By info| 2016-03-03T17:48:50+00:00 April 30th, 2012|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: 0001106644, 2012-04-30, 2834, 8-K, CPHI, PHARMACEUTICAL PREPARATIONS|0 Comments

MR [Mindray Medical International] 20-F: (Original Filing)

[U.S.GAAP International Financial Reporting Standards issued STYLE="font-family:Times New Roman" SIZE="2">by the International Accounting Standards Board Other Page INTRODUCTION 1 PARTI 3 ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT ANDVISERS 3 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 3 ITEM 3. KEY INFORMATION 3 ITEM 4. INFORMATION ON THEMPANY] [LIST OF SUBSIDIARIES STYLE="font-family:Times New Roman" SIZE="2"> Mindray (UK) Limited,orporated in the United Kingdom Mindray Research and Development Limited,orporated in the British Virgin Islands Mindray Global Limited,orporated in the British Virgin Islands Shenzhen Mindray Bio-Medical Electronicsorporated in the Peoples Republic of China Beijing Shen Mindray Medical Electronics Technology Research Instituteorporated in the Peoples Republic of] [CERTIFICATION STYLE="font-family:Times New Roman" SIZE="2">I, Xu Hang, certify that: 1. I have reviewed this annual report on Form 20-F of Mindray Medical International Limited; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [CERTIFICATION STYLE="font-family:Times New Roman" SIZE="2">I, Li Xiting, certify that: 1. I have reviewed this annual report on Form 20-F of Mindray Medical International Limited; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [CERTIFICATION STYLE="font-family:Times New Roman" SIZE="2">I,ex Lung, certify that: 1. I have reviewed this annual report on Form 20-F of Mindray Medical International Limited; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION Xu Hang Chairman and-Chief Executive Officer Li Xiting Director,PresidentandCo-ChiefExecutiveOfficerex Lung Chief Financial Officer d293110dex131.htm 6 EX-13.1] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM STYLE="font-family:Times New Roman" SIZE="2"> We herebynsent to theorporation by reference in the Registration Statement on FormS-8 (No. 333-178896) of Mindray Medical International Limited of our reportted April30, 2012 relating to the financial statements and the effectiveness of internalntrol over financial reporting, which appears in this Form 20-F. Wesonsent]

By info| 2016-02-08T05:10:52+00:00 April 30th, 2012|Categories: Chinese Stocks, MR, SEC Original|Tags: 0001373060, 20-F, 2012-04-30, 3841, MR, SURGICAL and MEDICAL INSTRUMENTS and APPARATUS|0 Comments

MR [Mindray Medical International] 20-F: U.S.GAAP International Financial Reporting Standards issued STYLE=”font-family:Times New

[U.S.GAAP International Financial Reporting Standards issued STYLE="font-family:Times New Roman" SIZE="2">by the International Accounting Standards Board Other Page INTRODUCTION 1 PARTI 3 ITEM 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT ANDVISERS 3 ITEM 2. OFFER STATISTICS AND EXPECTED TIMETABLE 3 ITEM 3. KEY INFORMATION 3 ITEM 4. INFORMATION ON THEMPANY] [LIST OF SUBSIDIARIES STYLE="font-family:Times New Roman" SIZE="2"> Mindray (UK) Limited,orporated in the United Kingdom Mindray Research and Development Limited,orporated in the British Virgin Islands Mindray Global Limited,orporated in the British Virgin Islands Shenzhen Mindray Bio-Medical Electronicsorporated in the Peoples Republic of China Beijing Shen Mindray Medical Electronics Technology Research Instituteorporated in the Peoples Republic of] [CERTIFICATION STYLE="font-family:Times New Roman" SIZE="2">I, Xu Hang, certify that: 1. I have reviewed this annual report on Form 20-F of Mindray Medical International Limited; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [CERTIFICATION STYLE="font-family:Times New Roman" SIZE="2">I, Li Xiting, certify that: 1. I have reviewed this annual report on Form 20-F of Mindray Medical International Limited; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light] [CERTIFICATION STYLE="font-family:Times New Roman" SIZE="2">I,ex Lung, certify that: 1. I have reviewed this annual report on Form 20-F of Mindray Medical International Limited; 2. Based on my knowledge, this report does notntain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of] [CERTIFICATION Xu Hang Chairman and-Chief Executive Officer Li Xiting Director,PresidentandCo-ChiefExecutiveOfficerex Lung Chief Financial Officer d293110dex131.htm 6 EX-13.1] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM STYLE="font-family:Times New Roman" SIZE="2"> We herebynsent to theorporation by reference in the Registration Statement on FormS-8 (No. 333-178896) of Mindray Medical International Limited of our reportted April30, 2012 relating to the financial statements and the effectiveness of internalntrol over financial reporting, which appears in this Form 20-F. Wesonsent]

By info| 2016-02-08T05:11:26+00:00 April 30th, 2012|Categories: Chinese Stocks, MR, Webplus ver|Tags: 0001373060, 20-F, 2012-04-30, 3841, MR, SURGICAL and MEDICAL INSTRUMENTS and APPARATUS|0 Comments

CLNT [Cleantech Solutions International,] PRE 14A: SCHEDULE 14A INFORMATION x o Check the appropriate

[SCHEDULE 14A INFORMATION x o Check the appropriate box: x Preliminary Proxy Statement o o Definitive Proxy Statement o Definitiveditional Materials o Cleantech Solutions International, Payment of Filing Fee (Check the appropriate box): x No fee required. o Feemputed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.]

By info| 2016-02-13T14:32:01+00:00 April 30th, 2012|Categories: Chinese Stocks, CLNT, Webplus ver|Tags: 0000819926, 2012-04-30, 3550, CLNT, PRE_14A, SPECIAL INDUSTRY MACHINERY (NO METALWORKING MACHINERY)|0 Comments

CO [China Cord Blood] 6-K: (Original Filing)

[Execution Version CONVERTIBLE NOTE PURCHASE among CHINA CORD BLOOD CORPORATION and KKR CHINA HEALTHCARE INVESTMENT LIMITED Dated April 12, 2012 Paul, Weiss, Rifkind, Wharton & Garrison Solicitors and International Lawyers 12th Floor, Hong Kong Club Building 3A Chater Road Central Hong Kong TABLE OF CONTENTS Page Section 1 2 Section 2 9 Section 3 9 Section 4 14 Section 5] [SENIOR CONVERTIBLE NOTE SECURITIES ACT CHINA CORD BLOOD CORPORATION 7% SENIOR CONVERTIBLE NOTE Original Principal Amount: US$65,000,000 Holder Principal and Issuance Date and Note Notes Other Notes Registration Rights Agreement FOR VALUE RECEIVED, China Cord Blood Corporation, an exempted company with limited liability incorporated in the Cayman Islands (the “Company”), hereby promises to pay to the order of KKR China] [EXECUTION COPY REGISTRATION RIGHTS AGREEMENT between CHINA CORD BLOOD CORPORATION and KKR CHINA HEALTHCARE INVESTMENT LIMITED April 27 Dated Paul, Weiss, Rifkind, Wharton & Garrison Solicitors and International Lawyers 12th Floor, Hong Kong Club Building 3A Chater Road Central Hong Kong TABLE OF CONTENTS Page Section 1 DEFINITIONS 1 Section 2 GENERAL; SECURITIES SUBJECT TO THIS AGREEMENT 5 Section 3] [DIRECTOR INDEMNIFICATION AGREEMENT between CHINA CORD BLOOD CORPORATION and JULIAN J. WOLHARDT Dated April 27, 2012 Paul, Weiss, Rifkind, Wharton & Garrison Solicitors and International Lawyers 12th Floor, Hong Kong Club Building 3A Chater Road Central Hong Kong TABLE OF CONTENTS Contents Page 1. Interpretation 1 2. Indemnity 3 3. Limitations on indemnity 3 4. Company’s liability 4 5. 4] [Execution Copy INDEMNIFICATION PRIORITY AND INFORMATION SHARING AGREEMENT Agreement KKR CHINA HEALTHCARE INVESTMENT LIMITED Investor KKR Company This INDEMNIFICATION PRIORITY AND INFORMATION SHARING AGREEMENT, dated as of April 27, 2012 (this “ Company Indemnification Agreement KKR Indemnified Parties WHEREAS, the Company has entered into a Convertible Note Purchase Agreement dated as of April 12, 2012 (the “ KKR Director WHEREAS,] [China Cord Blood Corporation Announces Completion of $65 Million Convertible Debt Financing with KKR HONG KONG, China, April 27, 2012 China Cord Blood Corporation (NYSE: CO) (“CCBC” or “the Company”), the first and largest cord blood banking operator in China, today announced that it has successfully closed a US$65 million convertible debt financing with funds affiliated with KKR China Growth]

By info| 2016-02-29T14:49:20+00:00 April 30th, 2012|Categories: Chinese Stocks, CO, SEC Original|Tags: 0001467808, 2012-04-30, 6-K, 6770, BLANK CHECKS, CO|0 Comments

CO [China Cord Blood] 6-K: Execution Version CONVERTIBLE NOTE PURCHASE among CHINA CORD

[Execution Version CONVERTIBLE NOTE PURCHASE among CHINA CORD BLOOD CORPORATION and KKR CHINA HEALTHCARE INVESTMENT LIMITED Dated April 12, 2012 Paul, Weiss, Rifkind, Wharton & Garrison Solicitors and International Lawyers 12th Floor, Hong Kong Club Building 3A Chater Road Central Hong Kong TABLE OF CONTENTS Page Section 1 2 Section 2 9 Section 3 9 Section 4 14 Section 5] [SENIOR CONVERTIBLE NOTE SECURITIES ACT CHINA CORD BLOOD CORPORATION 7% SENIOR CONVERTIBLE NOTE Original Principal Amount: US$65,000,000 Holder Principal and Issuance Date and Note Notes Other Notes Registration Rights Agreement FOR VALUE RECEIVED, China Cord Blood Corporation, an exempted company with limited liability incorporated in the Cayman Islands (the “Company”), hereby promises to pay to the order of KKR China] [EXECUTION COPY REGISTRATION RIGHTS AGREEMENT between CHINA CORD BLOOD CORPORATION and KKR CHINA HEALTHCARE INVESTMENT LIMITED April 27 Dated Paul, Weiss, Rifkind, Wharton & Garrison Solicitors and International Lawyers 12th Floor, Hong Kong Club Building 3A Chater Road Central Hong Kong TABLE OF CONTENTS Page Section 1 DEFINITIONS 1 Section 2 GENERAL; SECURITIES SUBJECT TO THIS AGREEMENT 5 Section 3] [DIRECTOR INDEMNIFICATION AGREEMENT between CHINA CORD BLOOD CORPORATION and JULIAN J. WOLHARDT Dated April 27, 2012 Paul, Weiss, Rifkind, Wharton & Garrison Solicitors and International Lawyers 12th Floor, Hong Kong Club Building 3A Chater Road Central Hong Kong TABLE OF CONTENTS Contents Page 1. Interpretation 1 2. Indemnity 3 3. Limitations on indemnity 3 4. Company’s liability 4 5. 4] [Execution Copy INDEMNIFICATION PRIORITY AND INFORMATION SHARING AGREEMENT Agreement KKR CHINA HEALTHCARE INVESTMENT LIMITED Investor KKR Company This INDEMNIFICATION PRIORITY AND INFORMATION SHARING AGREEMENT, dated as of April 27, 2012 (this “ Company Indemnification Agreement KKR Indemnified Parties WHEREAS, the Company has entered into a Convertible Note Purchase Agreement dated as of April 12, 2012 (the “ KKR Director WHEREAS,] [China Cord Blood Corporation Announces Completion of $65 Million Convertible Debt Financing with KKR HONG KONG, China, April 27, 2012 China Cord Blood Corporation (NYSE: CO) (“CCBC” or “the Company”), the first and largest cord blood banking operator in China, today announced that it has successfully closed a US$65 million convertible debt financing with funds affiliated with KKR China Growth]

By info| 2016-02-29T14:50:16+00:00 April 30th, 2012|Categories: Chinese Stocks, CO, Webplus ver|Tags: 0001467808, 2012-04-30, 6-K, 6770, BLANK CHECKS, CO|0 Comments

CO [Chinard Bloodrp] 6-K: Execution VersionNVERTIBLE NOTE PURCHASE among CHINARD BLOODRPORATION andR

[Execution VersionNVERTIBLE NOTE PURCHASE among CHINARD BLOODRPORATION andR CHINA HEALTHCARE INVESTMENT LIMITEDted April 12, 2012 Paul, Weiss, Rifkind, Wharton & Garrison Solicitors and International Lawyers 12th Floor, Hong Kong Club Building 3A Chater Road Central Hong Kong TABLE OFNTENTS Page Section 1 2 Section 2] [SENIORNVERTIBLE NOTE SECURITIES ACT CHINARD BLOODRPORATION 7% SENIORNVERTIBLE NOTE Original Principal Amount: US$65,000,000 Holder Principal and Issuancete and Note Notes Other Notes Registration Rightsreement FOR VALUE RECEIVED, Chinard Bloodrporation, an exemptedmpany with limited liabilityorporated in theyman Islands (thempany), hereby promises to pay to the order ofR China Healthcare Investment Limited or registeredsigns (the] [EXECUTIONPY REGISTRATION RIGHTSREEMENT between CHINARD BLOODRPORATION andR CHINA HEALTHCARE INVESTMENT LIMITED April 27ted Paul, Weiss, Rifkind, Wharton & Garrison Solicitors and International Lawyers 12th Floor, Hong Kong Club Building 3A Chater Road Central Hong Kong TABLE OFNTENTS Page Section 1 DEFINITIONS 1 Section 2 GENERAL; SECURITIES SUBJECT TO THISREEMENT] [DIRECTOR INDEMNIFICATIONREEMENT between CHINARD BLOODRPORATION and JULIAN J. WOLHARDTted April 27, 2012 Paul, Weiss, Rifkind, Wharton & Garrison Solicitors and International Lawyers 12th Floor, Hong Kong Club Building 3A Chater Road Central Hong Kong TABLE OFNTENTSntents Page 1. Interpretation 1 2. Indemnity 3 3. Limitations on indemnity] [Executionpy INDEMNIFICATION PRIORITY AND INFORMATION SHARINGREEMENTreementR CHINA HEALTHCARE INVESTMENT LIMITED InvestorRmpany This INDEMNIFICATION PRIORITY AND INFORMATION SHARINGREEMENT,ted of April 27, 2012 (thismpany IndemnificationreementR Indemnified Parties WHEREAS, thempany has entered into anvertible Note Purchasereementted of April 12, 2012 (the] [Chinard Bloodrporation Announcesmpletion of $65 Millionnvertible Debt Financing withR HONG KONG, China, April 27, 2012 Chinard Bloodrporation (NYSE:) (CCBC or thempany), the first and largestrd blood banking operator in China, today announced that it has successfully closed a US$65 millionnvertible debt financing with funds affiliated withR China Growth Fund L.P., a China-focused investment fund managed]

By info| 2016-02-04T17:25:30+00:00 April 30th, 2012|Categories: Chinese Stocks, CO, Webplus ver|Tags: 0001467808, 2012-04-30, 6-K, 6770, BLANK CHECKS, CO|0 Comments

SIMO [Silicon Motion Technology] 20-F: (Original Filing)

[Title of each class Name of each exchange on which registered Ordinary shares, par value US$0.01 per share* American Depositary Shares, each representing four ordinary shares Nasdaq Global Select Market * Not for trading, but only in connection with the listing on the Nasdaq Global Select Market of American Depositary Shares, or ADSs, each representing four ordinary shares. None None] [Subsidiaries of Silicon Motion Technology Corporation Lake Tahoe Investment Corporation, a corporation organized under the laws of the Cayman Islands (Lake Tahoe). Silicon Motion Korea Ltd., a corporation organized under the laws of Korea (SMK, a wholly-owned subsidiary of Lake Tahoe). FCI, Inc., a corporation organized under the laws of Korea (FCI, a wholly-owned subsidiary of Lake Tahoe). Silicon Motion,] [I, Wallace C. Kou, certify that: 1. I have reviewed this annual report on Form 20-F of Silicon Motion Technology Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [I, Riyadh Lai, certify that: 1. I have reviewed this annual report on Form 20-F of Silicon Motion Technology Corporation; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [Wallace C. Kou, President & Chief Executive Officer Riyadh Lai, Chief Financial Officer EX-13.1 5 d306662dex131.htm CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Deloitte & Touche Taipei, Taiwan Republic of China April 25, 2012 EX-23.1 6 d306662dex231.htm CONSENT OF DELOITTE & TOUCHE]

By info| 2016-03-14T19:33:33+00:00 April 30th, 2012|Categories: Chinese Stocks, SEC Original, SIMO|Tags: 0001329394, 20-F, 2012-04-30, 3674, SEMICONDUCTORS and RELATED DEVICES, SIMO|0 Comments